Live federal data · NADAC weekly · Part D CY24

Triazolam Diazepam

Triazolam vs Diazepam — $81.2M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Benzodiazepine
Triazolam
Brand: Halcion
First FDA approval:
Benzodiazepine
Diazepam
Brand: Valium
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$0.340Per unit
$0.022Per unit
Average NADACAcross all dosage forms and strengths
$0.346Up to $0.350
$90.66Up to $366.86
Generic manufacturersActive ANDA holders — FDA Orange Book
24 total ANDAs filed
1635 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$5.3MFull year
$75.9MFull year
Part D claims (CY24)Total fills, all strengths
155K78K beneficiaries
4.5M1.6M beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$34Per claim, all NDCs
$17Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
14Minimal friction
965Substantial friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
0None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
DiscontinuedSee drug profile
NoneClear
Generic availableFDA Orange Book
Yes2 manufacturers
Yes16 manufacturers